Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer’s Quest For COVID Vaccine Correlates Of Protection Running Into Roadblocks

Executive Summary

Pfizer scientists said they are having trouble identifying an immune correlate of protection for the company's COVID-19 vaccine, while other scientists expressed optimism that neutralizing antibodies might eventually be able to be used as a correlate, though there were some questions raised about using them for booster decision making.

You may also be interested in...

COVID Vaccines: US FDA Should Play More Activist Role In Development Of Modified Formulations

Advisory committee tells FDA that the agency, not vaccine manufacturers, should dictate the conversation around variants and reformulations; panelists also want better government research on immune correlates of protection ahead of any decision on a composition change.

Mix and Match COVID Boosters: Time Crunch For Data Review May Mean No Advisory Committee Vote

US FDA can’t say whether it will have its vaccine advisors vote on the heterologous uses of booster doses at its 14-15 October meeting of the Vaccines and Related Biological Products Advisory Committee because it is still reviewing the data. The Agency does not appear to need a formal company application or emergency use authorization amendment to allow this type of boosting.

From ‘Booster-For-All’ To ‘Pfizer-For-Some’: Lessons From The Third Shot Debate

Biden Administration met its self-declared goal of launching a booster campaign ‘the week of September 20’ – but with a more complex messaging challenge than anyone could have wanted after US FDA authorization and CDC recommendation for a ‘booster’ dose of Pfizer/BioNTech’s COVID vaccine left considerable confusion about who should get a third shot.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts